SCHEMBL4348393

SCHEMBL4348393

O=C(O)c1ccc(-c2cc(Cl)cc([N+](=O)[O-])c2O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.54
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
CASP6 P55212 1/20 0.47
TTR P02766 1/20 0.47
SRD5A2 P31213 1/20 0.44
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
POLB P06746 2/20 0.42
VCAM1 P19320 1/20 0.42
GPR35 Q9HC97 1/20 0.41
NSD2 O96028 1/20 0.41
PLA2G1B P04054 1/20 0.41
PLCG1 P19174 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404933 0.87 TTR (0.48) ERN1CASP6TTRLMNATDP1
SCHEMBL29386074 0.85 ERN1 (0.57) ERN1RXRARXRBCASP6TTR
SCHEMBL2404465 0.85 ERN1 (0.57) ERN1RXRARXRBCASP6TTR
SCHEMBL2405633 0.83 TTR (0.42) ERN1TTRMEN1KMT2ACRHBP
SCHEMBL4348195 0.82 CASP6 (0.48) ERN1CASP6TTRTSHRLMNA
SCHEMBL2407536 0.82 HCAR2 (0.46) ERN1CASP6TTRLMNATDP1
SCHEMBL2403588 0.82 CA1 (0.50) TTRLMNATDP1MEN1KMT2A
SCHEMBL2403547 0.81 GPR35 (0.55) ERN1CASP6TTRSRD5A2TSHR
Niclofolan SCHEMBL29385615 0.79 GPR35 (0.57) TTRTSHRLMNATDP1MEN1
Niclofolan SCHEMBL1498232 0.79 GPR35 (0.57) TTRTSHRLMNATDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ERN1 4239/4885RXRA 4434/4885RXRB 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.